Primary CNS lymphoma

  • Ferreri A
  • 1


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


The use of high-dose methotrexate (HD-MTX)-based chemotherapy, followed or not by whole-brain radiotherapy, is the commonest therapeutic approach for primary central nervous system lymphomas (PCNSL). The current therapeutic knowledge in this field comes from single-arm phase-II trials, meta-analyses of published series, large retrospective, multicentre series, and three randomized trials. Numerous methodological pitfalls were highlighted in both prospective and retrospective series, further hampering interpretation of results. Importantly, the first worldwide randomized trial with completed accrual was recently reported [1]. This trial demonstrated that, in patients

Author-supplied keywords

  • alkylating agent
  • antimetabolite
  • arm
  • blood brain barrier
  • brain
  • cell cycle
  • central nervous system
  • chemotherapy
  • cytarabine
  • cytotoxicity
  • drug megadose
  • human
  • ifosfamide
  • lymphoma
  • meta analysis
  • methotrexate
  • neoplasm
  • neurotoxicity
  • patient
  • phase 2 clinical trial
  • primary central nervous system lymphoma
  • radiotherapy
  • rituximab
  • temozolomide
  • thiotepa
  • toxicity
  • tumor cell

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • A J M Ferreri

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free